Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Hemostatic Profile Associated with Migraine with Aura

By LabMedica International staff writers
Posted on 31 May 2021
Nearly 15% of the population in the USA experiences migraine. More...
One subtype of migraine that is not well understood is migraine with aura (MA). Individuals who experience MA often see flashing lights, blind spots, or jagged lines in their visual field prior to onset of their migraine headaches.

Individuals who experience MA also face a heightened risk of stroke and cardiovascular disease, although scientists continue to explore why this correlation exists. Based on prior studies, it is controversial whether enhanced atherosclerosis among individuals with MA is likely to explain the migraine association with stroke, suggesting the existence of alternative mechanisms including endothelial activation or a potential role of hypercoagulability and microemboli.

An international team of Medical Scientists led by Brigham and Women's Hospital (Boston, MA, USA) investigated potential causal relationships between hemostatic profiles and migraine by leveraging largescale genome-wide association study (GWAS) summary statistics for migraine and migraine subtypes (MA and migraine without aura [MO]), and for eight hemostatic factors (including plasma levels or activities of fibrinogen, D-dimer, coagulation factor VII [FVII], coagulation factor VIII [FVIII], coagulation factor XI [FXI], von Willebrand factor [vWF], tissue plasminogen activator [tPA], and plasminogen activator inhibitor-1 [PAI-1] among up to 120,246 individuals), two hemostasis clinical tests (activated partial thromboplastin time [aPTT] and prothrombin time/international normalized ratio [PT/INR], which are commonly used to screen for coagulation-factor deficiencies), as well as serum concentrations of two forms of fibrinopeptide A (fibrinopeptide A [ADSGEGDFXAEGGGVR*] and phosphorylated fibrinopeptide A [ADpSGEGDFXAEGGGVR*]).

The investigators found a strong association between four coagulation factors and migraine susceptibility. They observed that genetically increased levels of three blood clotting factors: coagulation factor VIII, von Willebrand factor, and phosphorylated fibrinopeptide A, and genetically decreased levels of fibrinogen (a protein important in the late stages of the blood clotting process) were all associated, in part, with migraine susceptibility. Interestingly, scientists did not find this association among individuals who experience migraine without aura (MO), indicating a specific relationship between these hemostatic factors and MA.

Yanjun Guo, MD, PhD, of the Division of Preventative Medicine at the Brigham and the first author of the study, said, “It is very exciting that by using Mendelian randomization we were able to show that hemostatic factors are associated with MA. And because in the observational studies we saw that MA patients have a higher risk of stroke, these findings may reveal a potential connection between MA and stroke.”

The authors concluded that their findings suggest potential causal roles of genetically determined elevated FVIII, vWF, phosphorylated fibrinopeptide A, and decreased fibrinogen in migraine susceptibility, especially for MA, but the effects of FVIII and vWF on migraine are not independent from each other. The study was originally published online on April 1, 2021 in the journal Neurology.

Related Links:
Brigham and Women's Hospital



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.